Want to see SLN full AI Analyst Report?
Silence Therapeutics (SLN) Stock Statistics & Valuation Metrics
Total Valuation
Silence Therapeutics has a market cap or net worth of $1.23B. The enterprise value is $446.72M.
- Market Cap
- $1.23B
- Enterprise Value
- $446.72M
Share Statistics
Silence Therapeutics has 62,154,087 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 62,154,087
- Owned by Insiders
- 16.83%
- Owned by Institutions
- 5.99%
Financial Efficiency
Silence Therapeutics’s return on equity (ROE) is -1.42 and return on invested capital (ROIC) is -76.11%.
- Return on Equity (ROE)
- -1.42
- Return on Assets (ROA)
- -0.67
- Return on Invested Capital (ROIC)
- -76.11%
- Return on Capital Employed (ROCE)
- -0.76
- Revenue Per Employee
- 6,352.273
- Profits Per Employee
- -1.01M
- Employee Count
- 88
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Silence Therapeutics is -5.18. Silence Therapeutics’s PEG ratio is -0.38.
- PE Ratio
- -5.18
- PS Ratio
- 1518.61
- PB Ratio
- 8.08
- Price to FCF
- -22.03
- Price to Operating Cash Flow
- -7.35
- PEG Ratio
- -0.38
Income Statement
In the last 12 months, Silence Therapeutics had revenue of 559.00K and earned -88.61M in profits. Earnings per share was -5.67.
- Revenue
- 559.00K
- Gross Profit
- 344.00K
- Operating Income
- -89.75M
- Pretax Income
- -88.60M
- Net Income
- -88.61M
- EBITDA
- -88.05M
- Earnings Per Share (EPS)
- -5.67
Cash Flow
In the last 12 months, operating cash flow was -42.29M and capital expenditures -57,997, giving a free cash flow of -42.34M billion.
- Operating Cash Flow
- -42.29M
- Free Cash Flow
- -42.34M
- Free Cash Flow per Share
- -2.69
Dividends & Yields
Silence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.54%
- Earnings Yield
- -19.28%
Stock Price Statistics
- Beta
- 1.18
- 52-Week Price Change
- 170.18%
- 50-Day Moving Average
- 13.38
- 200-Day Moving Average
- 9.05
- Relative Strength Index (RSI)
- 78.90
- Average Volume (3m)
- 2.76M
Important Dates
Silence Therapeutics upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Silence Therapeutics as a current ratio of 8.72, with Debt / Equity ratio of 0.26%
- Current Ratio
- 8.72
- Quick Ratio
- 8.72
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.13
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Silence Therapeutics has paid 11.00K in taxes.
- Income Tax
- 11.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Silence Therapeutics EV to EBITDA ratio is -14.28, with an EV/FCF ratio of -20.33.
- EV to Sales
- 1401.50
- EV to EBITDA
- -14.28
- EV to Free Cash Flow
- -20.33
- EV to Operating Cash Flow
- -20.36
Balance Sheet
Silence Therapeutics has $72.05M in cash and marketable securities with $112.00K in debt, giving a net cash position of $71.94M billion.
- Cash & Marketable Securities
- $72.05M
- Total Debt
- $112.00K
- Net Cash
- $71.94M
- Net Cash Per Share
- $1.16
- Tangible Book Value Per Share
- $1.77
Margins
Gross margin is 51.00%, with operating margin of -10880.25%, and net profit margin of -9759.23%.
- Gross Margin
- 51.00%
- Operating Margin
- -10880.25%
- Pretax Margin
- -9758.90%
- Net Profit Margin
- -9759.23%
- EBITDA Margin
- -9814.00%
- EBIT Margin
- -9892.63%
Analyst Forecast
The average price target for Silence Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $23.00
- Price Target Upside
- 16.46% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- 55